Access DB# 87970

SEARCH REQUEST FORM

Scientific and Technical Informati n Center

Requester's Full Name: Hong Liu Examiner #: 77011 Date: 2/19/03
Art Unit: 1624 Phone Number 30 6-5814 Serial Number: 09/548,081
Mail Box and Bldg/Room Location: 4E01 (4E12) Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need. MEJ

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: _____

Inventors (please provide full names): _____

_____

Earliest Priority Filing Date: _____

***For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.**

Barb please!



see definitions of X, Y, A, Z in claim 1

see also provisos. Thanks!

Point of Contact:
Barb O'Bryen
Technical Information Specialist
STIC CM1 6A05 308-4291

****

STAFF USE ONLY

Searcher: BOB
Searcher Phone #: _____
Searcher Location: _____
Date Searcher Picked Up: _____
Date Completed: 2-24-03
Searcher Prep & Review Time: 30
Clerical Prep Time: _____
Online Time: 22

Type of Search

NA Sequence (#) _____
AA Sequence (#) _____
Structure (#) 4
Bibliographic _____
Litigation _____
Fulltext _____
Patent Family _____
Other _____

Vendors and cost where applicable

STN 401
Dialog _____
Questel/Orbit _____
Dr.Link _____
Lexis/Nexis _____
Sequence Systems _____
WWW/Internet _____
Other (specify) _____

PTO-1590 (8-01)

BioTech-Chem Library
Search Results
Feedback Form (Optional)

Scientific & Technical Information Center

The search results generated for your recent request are attached. If you have any questions or comments (compliments or complaints) about the scope or the results of the search, please contact *the BioTech-Chem searcher* who conducted the search *or contact*:

Mary Hale, Supervisor, 308-4258
CM-1 Room 1E01

Voluntary Results Feedback Form

this search didnt pick up X=NH

- *I am an examiner in Workgroup:* *(Example: 1610)*
- *Relevant prior art **found**, search results used as follows:*
  - ☐ 102 rejection
  - ☐ 103 rejection
  - ☐ Cited as being of interest.
  - ☐ Helped examiner better understand the invention.
  - ☐ Helped examiner better understand the state of the art in their technology.

Types of relevant prior art found:

- ☐ Foreign Patent(s)
- ☐ Non-Patent Literature
  (journal articles, conference proceedings, new product announcements etc.)

- *Relevant prior art **not found**:*
  - ☐ Results verified the lack of relevant prior art (helped determine patentability).
  - ☐ Search results were not useful in determining patentability or understanding the invention.

Other Comments:

Drop off completed forms at the **Circulation Desk CM-1**, or send to Mary Hale, **CM1-1E01** or **mary.hale@uspto.gov**

```
=> fil reg; d stat que l10; fil capl; d que nos l11; fil uspatf; d que nos l12
FILE 'REGISTRY' ENTERED AT 10:45:47 ON 24 FEB 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   21 FEB 2003  HIGHEST RN 493666-74-3
DICTIONARY FILE UPDATES:  21 FEB 2003  HIGHEST RN 493666-74-3

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf
```

L1 STR



C≡O @12 13 S≡O @14 15 C≡N≡CN @16 17 18

C≡S @19 20 C≡CH—NO2 @21 22 23 C≡C—CN @24 25 26 C≡N—SO2 @27 28 29 C≡CH—CN @30 31 32

N @33 C @34 O—N @35 36 O—C @37 38 N—N @39 40 N—C @41 42

Ak—N @43 44 Ak—C @45 46 O—Ak—N @47 48 49 N—Ak—C @50 51 52

full file search done on this structure

```
VAR G1=CH2/12/14/16/19/SO2/21/24/30/27
VAR G2=33/34/35/37/39/41/43/45/47/50
NODE ATTRIBUTES:
NSPEC   IS R      AT  33
NSPEC   IS RC     AT  34
NSPEC   IS R      AT  36
NSPEC   IS RC     AT  38
NSPEC   IS R      AT  40
NSPEC   IS RC     AT  42
NSPEC   IS R      AT  44
NSPEC   IS RC     AT  46
NSPEC   IS R      AT  49
NSPEC   IS RC     AT  52
DEFAULT MLEVEL IS ATOM
```

= ring or chain node

= chain node

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 53

STEREO ATTRIBUTES: NONE
L3 STR



these 2 structures "not"-ed out of answer set (provisos)

NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE
L4 STR





Cb @20 Ak @21

VAR G1=PH/14/15/19/20/21
NODE ATTRIBUTES:
CONNECT IS E1 RC AT 20
CONNECT IS E1 RC AT 21
CONNECT IS E1 RC AT 23
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS M3-X8 C AT 20

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 23

STEREO ATTRIBUTES: NONE
L6 585 SEA FILE=REGISTRY SSS FUL L1 NOT (L3 OR L4)
L8 STR



C≡O @12 13

S≡O @14 15

C≡N—CN @16 17 18

C≡S @19 20

C≡CH—NO2 @21 22 23



C≡C—CN @24 25 26

C≡N—SO2 @27 28 29

C≡CH—CN @30 31 32

N @33

C @34

O—N @35 36

O—C @37 38

N—N @39 40

N—C @41 42

Ak—N @43 44

Ak—C @45 46

O—Ak—N @47 48 49

N—Ak—C @50 51 52

C~CF3 @54 55

Page 1-A

C~Ak @56 57

C~Ak~Cb @58 59 60

C~Cb @61 62

C~Cb~Ak @63 64 65



A = any non-hydrogen atom = ring nodes & bonds

Page 2-A
VAR G1=CH2/12/14/16/19/SO2/21/24/30/27
VAR G2=33/34/35/37/39/41/43/45/47/50
VAR G3=CH2/54/56/58/61/63/67
NODE ATTRIBUTES:
NSPEC IS R AT 33
NSPEC IS RC AT 34
NSPEC IS R AT 36
NSPEC IS RC AT 38
NSPEC IS R AT 40
NSPEC IS RC AT 42
NSPEC IS R AT 44
NSPEC IS RC AT 46
NSPEC IS R AT 49
NSPEC IS RC AT 52
NSPEC IS R AT 66
NSPEC IS R AT 68
CONNECT IS E1 RC AT 57
CONNECT IS E1 RC AT 62
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

subset search done on this structure

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 68

STEREO ATTRIBUTES: NONE
L10 165 SEA FILE=REGISTRY SUB=L6 SSS FUL L8

100.0% PROCESSED 585 ITERATIONS 165 ANSWERS
SEARCH TIME: 00.00.01

FILE 'CAPLUS' ENTERED AT 10:45:47 ON 24 FEB 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 24 Feb 2003 VOL 138 ISS 9
FILE LAST UPDATED: 23 Feb 2003 (20030223/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

L1		STR
L3		STR
L4		STR
L6	585	SEA FILE=REGISTRY SSS FUL L1 NOT (L3 OR L4)
L8		STR
L10	165	SEA FILE=REGISTRY SUB=L6 SSS FUL L8
L11	18	SEA FILE=CAPLUS ABB=ON L10

FILE 'USPATFULL' ENTERED AT 10:45:47 ON 24 FEB 2003

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 20 Feb 2003 (20030220/PD)
FILE LAST UPDATED: 20 Feb 2003 (20030220/ED)
HIGHEST GRANTED PATENT NUMBER: US6523178
HIGHEST APPLICATION PUBLICATION NUMBER: US2003037360
CA INDEXING IS CURRENT THROUGH 20 Feb 2003 (20030220/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 20 Feb 2003 (20030220/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2002
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Dec 2002

>>> USPAT2 is now available. USPATFULL contains full text of the original, i.e., the earliest published granted patents or applications. USPAT2 contains full text of the latest US publications, starting in 2001, for the inventions covered in USPATFULL. A USPATFULL record contains not only the original published document but also a list of any subsequent publications. The publication number, patent kind code, and publication date for all the US publications for an invention are displayed in the PI (Patent Information) field of USPATFULL records and may be searched in standard search fields, e.g., /PN, /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<

```
>>>  through the new cluster USPATALL.  Type FILE USPATALL to          <<<
>>>  enter this cluster.                                               <<<
>>>                                                                    <<<
>>>  Use USPATALL when searching terms such as patent assignees,       <<<
>>>  classifications, or claims, that may potentially change from     <<<
>>>  the earliest to the latest publication.                           <<<

This file contains CAS Registry Numbers for easy and accurate
substance identification.


L1              STR
L3              STR
L4              STR
L6          585 SEA FILE=REGISTRY SSS FUL L1 NOT (L3 OR L4)
L8              STR
L10         165 SEA FILE=REGISTRY SUB=L6 SSS FUL L8
L12           8 SEA FILE=USPATFULL ABB=ON  L10


=> dup rem l11,l12
FILE 'CAPLUS' ENTERED AT 10:45:54 ON 24 FEB 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 10:45:54 ON 24 FEB 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
PROCESSING COMPLETED FOR L11
PROCESSING COMPLETED FOR L12
L14           25 DUP REM L11 L12 (1 DUPLICATE REMOVED)
                 ANSWERS '1-18' FROM FILE CAPLUS
                 ANSWERS '19-25' FROM FILE USPATFULL

=> d ibib abs hitstr 1-25; fil cao; d que nos l13; fil hom

L14  ANSWER 1 OF 25  CAPLUS  COPYRIGHT 2003 ACS        DUPLICATE 1
ACCESSION NUMBER:         1980:146611  CAPLUS
DOCUMENT NUMBER:          92:146611
TITLE:                    Substituted 3,6-dihydro-1(2H)-pyridinylpropanols
INVENTOR(S):              Hauck, Frederic P.; Fox, Rita T.; Watrous, John R.
PATENT ASSIGNEE(S):       Squibb, E. R., and Sons, Inc., USA
SOURCE:                   U.S., 7 pp.
                          CODEN: USXXAM
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   2
PATENT INFORMATION:

     PATENT NO.        KIND  DATE           APPLICATION NO.   DATE
     ---------------   ----  --------       ---------------   --------
     US 4169200         A    19790925       US 1977-824378    19770815
     US 4127579         A    19781128       US 1977-855038    19771125
     CA 1113937         A1   19811208       CA 1978-299457    19780321
     GB 1596357         A    19810826       GB 1978-12506     19780330
     FR 2386528         A1   19781103       FR 1978-9535      19780331
     FR 2386528         B1   19810724
     DE 2814799         A1   19781019       DE 1978-2814799   19780405
PRIORITY APPLN. INFO.:                  US 1977-784888      19770405
                                        US 1977-824378      19770815
                                        US 1977-855038      19771125
GI
```



I





AB (Tetrahydropyridyl)isopropanols I [n = 0, 1, 2; R = alkanoyl; R1 = x-phenyl-1,2,3,6-tetrahydro-1-pyridyl, A, x-styryl-1,2,3,6-tetrahydro-1-pyridyl, 4-(2-benzoxazolyl)-1,2,3,6-tetrahydro-1-pyridyl, 1,2,3,4-tetrahydroisoquinolin-2-yl, B], useful as antihypertensives (no data), were prepd. from the tetrahydropyridines and the resp. glycidyl-substituted bicyclic compds. Thus, a mixt. of 5-glycidyl-2,3,4a,8a-tetraacetoxydecalin, 4-phenyl-1,2,3,6-tetrahydropyridine, C6H6, and EtOH was stirred .apprx.16h at 55-7.degree. to yield I (n = 1, R = Ac, R1 = 4-phenyl-1,2,3,6-tetrahydro-1-pyridyl).

IT **72717-36-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 72717-36-3 CAPLUS

CN 2,3,4a,8a-Naphthalenetetrol, octahydro-5-[2-hydroxy-3-(1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propyl]- (9CI) (CA INDEX NAME)



L14 ANSWER 2 OF 25 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:368319 CAPLUS

DOCUMENT NUMBER: 136:369716

TITLE: New use of 4,5,6,7-tetrahydroimidazo-[4,5-c]pyridine derivatives as inhibitors of semicarbazide-sensitive amine oxidase (SSAO) for treatment of, e.g., diabetic complications.

INVENTOR(S): Caldirola, Patrizia; Besencon, Olivier; Olsson, Rolf; Oehman, Johan

PATENT ASSIGNEE(S): Biovitrum AB, Swed.

SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2

Searched by Barb O'Bryen, STIC 308-4291

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002038153	A1	20020516	WO 2001-SE2523	20011109
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002014505	A5	20020521	AU 2002-14505	20011109
US 2002198189	A1	20021226	US 2001-45319	20011109

PRIORITY APPLN. INFO.: SE 2000-4101 A 20001109
US 2000-252156P P 20001120
WO 2001-SE2523 W 20011109

OTHER SOURCE(S): MARPAT 136:369716
GI



I



II

AB The invention relates to the use of title compds. I for the treatment or prophylaxis of SSAO-mediated complications, such as those of diabetes [wherein: R1 = H or CONHR5; R2 = H, COOR5, COR5, CONHR5, or C(S)NHR5; R3 = H, C1-8 alkyl, or (CH2)nAr; R4 = H, Ar, or C1-8 alkyl; and R5 = H, (CH2)nAr, (CH2)nOAr, C1-8 alkyl contg. 0-2 O atoms and optionally substituted with 0-5 halogen atoms, or a polyether chain having the formula (CH2)xO(CH2)yO(CH2)zCH3; n = 0-4; m = 0-2; x, y = 2-4; z = 0-3; Ar = (un)substituted Ph, 1-naphthyl, or 2-naphthyl, cinnamoyl, (un)substituted benzyl, 1,1-diphenylethyl, (un)substituted mono- or bicyclic heterocyclic ring (furyl, pyrrolyl, triazolyl, diazolyl, oxazolyl, thiazolyl, oxadiazolyl, isothiazolyl, isoxazolyl, thiadiazolyl, pyridyl, pyrimidyl, pyrazinyl, thienyl, imidazolyl, pyrazolyl, indolyl, quinolinyl, isoquinolinyl, benzofuryl, benzothienyl, benzoxadiazolyl), 2-, 3-, or 4-pyridyl, or a 5- to 7-membered (un)satd. heterocyclic ring each contg. 1-4 N/O/S atoms, with optional H, C1-6 alkyl, or CF3CO at ring N]. Approx. 40 compds. were prepd. For instance, cyclocondensation of histamine di-HCl with acetaldehyde in aq. MeOH in the presence of NaOH gave the invention compd. 4-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine (isolated as di-HCl salt), which reacted with benzyl chloroformate and K2CO3 in CHCl3 to give title compd. II. In tests against human umbilical arterial SSAO, using both H2O2 and aldehyde detection methods, compds. I at 12 .mu.M gave 1-97% inhibition.

IT **424837-38-7P**, Benzyl 4-ethyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate trifluoroacetate **424837-55-8P**, 4-Phenyl-5-(phenoxyacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine trifluoroacetate

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; prepn. of tetrahydroimidazopyridine derivs. as SSAO inhibitors for treatment of diabetic complications)

RN 424837-38-7 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 4-ethyl-1,4,6,7-tetrahydro-, phenylmethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 424837-37-6
CMF C16 H19 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 424837-55-8 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine, 4,5,6,7-tetrahydro-5-(phenoxyacetyl)-4-phenyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 424837-54-7
CMF C20 H19 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT **424837-36-5P**, Methyl 4-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate **424837-40-1P**, Benzyl 4-phenyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate trifluoroacetate **424837-41-2P**, Benzyl 4-benzyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate **424837-43-4P**, Benzyl 4-propyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate trifluoroacetate **424837-45-6P**, Methyl 4-ethyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate trifluoroacetate **424837-47-8P**, Methyl 4-propyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate trifluoroacetate **424837-49-0P**, Methyl 4-phenyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate trifluoroacetate **424837-51-4P**, 4-Ethyl-5-(phenoxyacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine trifluoroacetate **424837-53-6P**, 4-Propyl-5-(phenoxyacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine trifluoroacetate **424837-57-0P**, Cyclopentyl 4-ethyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate trifluoroacetate **424837-59-2P**, Cyclopentyl 4-propyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate trifluoroacetate **424837-61-6P**, Cyclopentyl 4-phenyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate trifluoroacetate **424837-63-8P**, 4-Fluorophenyl 4-ethyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate trifluoroacetate **424837-65-0P**, 4-Fluorophenyl 4-propyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate trifluoroacetate **424837-66-1P**, 2-Methoxyethyl 4-ethyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate **424837-67-2P**, 2-Methoxyethyl 4-propyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate **424837-68-3P**, 2-Methoxyethyl 4-phenyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate **424837-69-4P**, Benzyl 4-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate **424837-70-7P**, 4-Methyl-5-(phenoxyacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine **424837-71-8P**, Allyl 4-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate **424837-72-9P**, Allyl 4-ethyl-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate **424837-73-0P**, Allyl 4-propyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate **424837-74-1P**, 2,2,2-Trichloroethyl 4-ethyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate **424837-75-2P**, Allyl 4-benzyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate **424837-76-3P**, 2,2,2-Trichloroethyl 4-propyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate **424837-77-4P**, 2,2,2-Trichloroethyl 4-benzyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate **424837-78-5P**, 4-Nitrobenzyl 4-ethyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate **424837-79-6P**, 4-Nitrobenzyl 4-propyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate **424837-85-4P**, 4-Fluorophenyl 4-phenyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate trifluoroacetate
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of tetrahydroimidazopyridine derivs. as SSAO inhibitors for treatment of diabetic complications)

RN 424837-36-5 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 424837-40-1 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-phenyl-, phenylmethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 424837-39-8
CMF C20 H19 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 424837-41-2 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-(phenylmethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 424837-43-4 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-propyl-, phenylmethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 424837-42-3
CMF C17 H21 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 424837-45-6 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 4-ethyl-1,4,6,7-tetrahydro-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 424837-44-5
CMF C10 H15 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 424837-47-8 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-propyl-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 424837-46-7

CMF C11 H17 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 424837-49-0 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-phenyl-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 424837-48-9
CMF C14 H15 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 424837-51-4 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine, 4-ethyl-4,5,6,7-tetrahydro-5-(phenoxyacetyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 424837-50-3
CMF C16 H19 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 424837-53-6 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine, 4,5,6,7-tetrahydro-5-(phenoxyacetyl)-4-propyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 424837-52-5
CMF C17 H21 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 424837-57-0 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 4-ethyl-1,4,6,7-tetrahydro-, cyclopentyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 424837-56-9
CMF C14 H21 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 424837-59-2 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-propyl-, cyclopentyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 424837-58-1
CMF C15 H23 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 424837-61-6 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-phenyl-, cyclopentyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 424837-60-5
CMF C18 H21 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 424837-63-8 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 4-ethyl-1,4,6,7-tetrahydro-, 4-fluorophenyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 424837-62-7
CMF C15 H16 F N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 424837-65-0 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-propyl-, 4-fluorophenyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 424837-64-9
CMF C16 H18 F N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 424837-66-1 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 4-ethyl-1,4,6,7-tetrahydro-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)



RN 424837-67-2 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-propyl-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)



RN 424837-68-3 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-phenyl-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)



RN 424837-69-4 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 424837-70-7 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine, 4,5,6,7-tetrahydro-4-methyl-5-(phenoxyacetyl)- (9CI) (CA INDEX NAME)



RN 424837-71-8 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-methyl-, 2-propenyl ester (9CI) (CA INDEX NAME)



RN 424837-72-9 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 4-ethyl-1,4,6,7-tetrahydro-, 2-propenyl ester (9CI) (CA INDEX NAME)



RN 424837-73-0 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-propyl-,

2-propenyl ester (9CI) (CA INDEX NAME)



RN 424837-74-1 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 4-ethyl-1,4,6,7-tetrahydro-, 2,2,2-trichloroethyl ester (9CI) (CA INDEX NAME)



RN 424837-75-2 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-(phenylmethyl)-, 2-propenyl ester (9CI) (CA INDEX NAME)



RN 424837-76-3 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-propyl-, 2,2,2-trichloroethyl ester (9CI) (CA INDEX NAME)



RN 424837-77-4 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-(phenylmethyl)-, 2,2,2-trichloroethyl ester (9CI) (CA INDEX NAME)



RN 424837-78-5 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 4-ethyl-1,4,6,7-tetrahydro-, (4-nitrophenyl)methyl ester (9CI) (CA INDEX NAME)



RN 424837-79-6 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-propyl-, (4-nitrophenyl)methyl ester (9CI) (CA INDEX NAME)



RN 424837-85-4 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-phenyl-, 4-fluorophenyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 424837-84-3
CMF C19 H16 F N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 3 OF 25 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:525970 CAPLUS

DOCUMENT NUMBER: 135:117216
TITLE: Macrocyclic peptidomimetic inhibitors of prenyl-protein transferase for inhibiting prenylation of Ras oncoprotein
INVENTOR(S): Desolms, S. Jane; Shaw, Anthony W.
PATENT ASSIGNEE(S): Merck + Co., Inc., USA
SOURCE: PCT Int. Appl., 142 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001051128	A1	20010719	WO 2001-US635	20010109
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6350755	B1	20020226	US 2001-757218	20010109

PRIORITY APPLN. INFO.: US 2000-175703P P 20000112
OTHER SOURCE(S): MARPAT 135:117216

AB The present invention is directed to peptidomimetic macrocyclic compds. which inhibit prenyl-protein transferase and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compns. contg. the compds. of this invention and methods for inhibiting prenyl-protein transferase and the prenylation of the oncogene protein Ras.

IT **350687-92-2P 350687-93-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(macrocyclic peptidomimetic inhibitors of prenyl-protein transferase for inhibiting prenylation of Ras oncoprotein)

RN 350687-92-2 CAPLUS
CN 3H-Imidazo[4,5-c]pyridine, 4-(4-cyano-3-fluorophenyl)-4,5,6,7-tetrahydro-5-[3-[[(3-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 350687-93-3 CAPLUS
CN 3H-Imidazo[4,5-c]pyridine, 4-(4-cyano-3-fluorophenyl)-4,5,6,7-tetrahydro-5-[3-[[(3-hydroxyphenyl)sulfonyl]amino]-1-oxopropyl]-3-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 4 OF 25 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:494661 CAPLUS
DOCUMENT NUMBER: 135:242187
TITLE: Synthesis of phenothiazine derivatives of spinaceamine and 2-azaspinaceamine
AUTHOR(S): Yutilov, Yu. M.; Smolyar, N. N.; Abramyants, M. G.; Tyurenkov, I. N.
CORPORATE SOURCE: Litvinenko Institute of Organic Chemistry, National Academy of Sciences of the Republic of Ukraine, Donetsk, Ukraine
SOURCE: Pharmaceutical Chemistry Journal (Translation of Khimiko-Farmatsevticheskii Zhurnal) (2001), 35(1), 15-17
CODEN: PCJOAU; ISSN: 0091-150X
PUBLISHER: Consultants Bureau
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 135:242187
AB Triazolo[4,5-c]pyridines and imidazo[4,5-c]pyridines are added to 2-chloro-10-(.beta.-chloropropionyl)phenothiazine, then reduced to give the spinaceamine and azaspinaceamine phenothiazine derivs.
IT **360794-61-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of phenothiazine derivs. of spinaceamine and 2-azaspinaceamine)
RN 360794-61-2 CAPLUS
CN 10H-Phenothiazine, 2-chloro-10-[1-oxo-3-(1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 5 OF 25 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:756706 CAPLUS
DOCUMENT NUMBER: 133:321882
TITLE: Preparation of substituted fused imidazoles for treatment and/or prevention of diseases and disorders

Searched by Barb O'Bryen, STIC 308-4291

related to the histamine H3 receptor

INVENTOR(S): Dorwald, Florencio Zaragoza; Andersen, Knud Erik; Jorgensen, Tine Krogh; Peschke, Bernd; Wulff, Birgitte Schjellerup; Pettersson, Ingrid; Rudolf, Klaus; Stenkamp, Dirk; Hurnaus, Rudolf; Muller, Stephan Georg; Krist, Bernd

PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.; Boehringer Ingelheim International, G.m.b.H.

SOURCE: PCT Int. Appl., 169 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000063208	A1	20001026	WO 2000-DK179	20000413
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1173438	A1	20020123	EP 2000-918714	20000413
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002542245	T2	20021210	JP 2000-612298	20000413

PRIORITY APPLN. INFO.:

DK 1999-508	A	19990416
DK 1999-1345	A	19990922
DK 2000-42	A	20000112
WO 2000-DK179	W	20000413

OTHER SOURCE(S): MARPAT 133:321882

GI



I



II

AB The title compds. [I; R1 = H, a functional group which can be converted to H in vivo; R2 = H, alkyl, halo, etc.; R3-R6 = H, CO2H, alkoxycarbonyl, etc.; m, n, p, q = 0-2; X = a bond, CH2, CO, etc.; Y = a bond, O, NR12 (R12 = H, alkyl, aryl, etc.); A = a bond, alkylene, alkenylene, etc.; Z = R13, OR13, SR13, etc. (R13 = H, alkyl, aryl, etc.)], useful for the treatment and/or prevention of diseases and disorders related to the histamine H3 receptor (more particularly, useful for the treatment and/or prevention of diseases and disorders, in which an interaction with the histamine H3 receptor is beneficial), were prepd. and formulated. E.g., treatment of 5-cyclohexylpentanoic acid with carbonyldiimidazole in DCM followed by addn. of 4,5,6,7-tetrahydroimidazo[4,5-c]pyridine in DCM afforded 24% II. Compds. I are effective at 0.05-10 mg/kg/day.

IT **303019-79-6P 303019-80-9P 303019-81-0P**
303019-82-1P 303019-83-2P 303019-84-3P
303019-86-5P 303019-87-6P 303019-89-8P
303020-01-1P 303020-03-3P 303020-05-5P
303020-07-7P 303020-09-9P 303020-11-3P
303020-13-5P 303020-15-7P 303020-17-9P
303020-19-1P 303020-21-5P 303020-23-7P
303020-25-9P 303020-27-1P 303020-29-3P
303020-31-7P 303020-33-9P 303020-35-1P
303020-37-3P 303020-39-5P 303020-41-9P
303020-43-1P 303020-45-3P 303020-47-5P
303020-49-7P 303020-51-1P 303020-53-3P
303020-55-5P 303020-57-7P 303020-59-9P
303020-61-3P 303020-63-5P 303020-64-6P
303020-65-7P 303020-66-8P 303020-67-9P
303020-68-0P 303020-69-1P 303020-70-4P
303020-71-5P 303020-72-6P 303020-74-8P
303020-75-9P 303020-77-1P 303020-79-3P
303020-81-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of substituted fused imidazoles for treatment and/or prevention of diseases and disorders related to the histamine H3 receptor)

RN 303019-79-6 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine, 5-(3-cyclohexyl-1-oxopropyl)-4,5,6,7-tetrahydro-4,4-dimethyl-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303019-78-5
CMF C17 H27 N3 O



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 303019-80-9 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine, 5-(5-cyclohexyl-1-oxopentyl)-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 303019-81-0 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine, 4,5,6,7-tetrahydro-5-(1-oxo-6-phenylhexyl)- (9CI) (CA INDEX NAME)



RN 303019-82-1 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine, 5-(3-cyclohexyl-1-oxopropyl)-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 303019-83-2 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine, 5-[3-(4-fluorophenyl)-1-oxopropyl]-4,5,6,7-tetrahydro-4-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 303019-84-3 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine, 4,5,6,7-tetrahydro-5-(1-oxo-3,3-diphenylpropyl)- (9CI) (CA INDEX NAME)



RN 303019-86-5 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine, 5-(3-cyclohexyl-1-oxopropyl)-4-ethyl-4,5,6,7-tetrahydro-4-methyl-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303019-85-4
CMF C18 H29 N3 O



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 303019-87-6 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine, 5-[3-(10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)-1-oxopropyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 303019-89-8 CAPLUS
CN Spiro[cyclobutane-1,4'-[4H]imidazo[4,5-c]pyridine], 1',5',6',7'-tetrahydro-5'-(3-cyclohexyl-1-oxopropyl)-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303019-88-7
CMF C18 H27 N3 O



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 303020-01-1 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine, 5-(cyclohexylacetyl)-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 303020-03-3 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-, [4-(1,1-dimethylethyl)phenyl]methyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-02-2
CMF C18 H23 N3 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 303020-05-5 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-, (2,3-dimethylphenyl)methyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-04-4
CMF C16 H19 N3 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 303020-07-7 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-, 2-phenylbutyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-06-6
CMF C17 H21 N3 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 303020-09-9 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-, (3-methoxyphenyl)methyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-08-8
CMF C15 H17 N3 O3



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 303020-11-3 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-, cyclopentylmethyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-10-2
CMF C13 H19 N3 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 303020-13-5 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-, (3-methylphenyl)methyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-12-4
CMF C15 H17 N3 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 303020-15-7 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-, (2-methylphenyl)methyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-14-6
CMF C15 H17 N3 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 303020-17-9 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-, 2-(2-methoxyphenyl)ethyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-16-8
CMF C16 H19 N3 O3



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 303020-19-1 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-, 2-(3-methylphenyl)ethyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-18-0
CMF C16 H19 N3 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 303020-21-5 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-, tricyclo[3.3.1.13,7]dec-1-ylmethyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-20-4
CMF C18 H25 N3 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 303020-23-7 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-, (3,4-dimethylphenyl)methyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-22-6
CMF C16 H19 N3 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 303020-25-9 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-, 3-cyclohexen-1-ylmethyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-24-8
CMF C14 H19 N3 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 303020-27-1 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-, (2,4-dimethylphenyl)methyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-26-0
CMF C16 H19 N3 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 303020-29-3 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-, 2-(2-methylphenyl)ethyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-28-2
CMF C16 H19 N3 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 303020-31-7 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-, 1-naphthalenylmethyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-30-6
CMF C18 H17 N3 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 303020-33-9 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-, [4-(1-methylethyl)phenyl]methyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-32-8
CMF C17 H21 N3 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 303020-35-1 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-, 2-naphthalenylmethyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-34-0
CMF C18 H17 N3 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 303020-37-3 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-, (2-methyl[1,1'-biphenyl]-3-yl)methyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-36-2
CMF C21 H21 N3 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 303020-39-5 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-, (4-ethylphenyl)methyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-38-4
CMF C16 H19 N3 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 303020-41-9 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-, 2-thienylmethyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-40-8
CMF C12 H13 N3 O2 S



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 303020-43-1 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-, 2-(2-thienyl)ethyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-42-0
CMF C13 H15 N3 O2 S



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 303020-45-3 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-, 2-(3-thienyl)ethyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-44-2
CMF C13 H15 N3 O2 S



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 303020-47-5 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-, (4-methoxy-2,3-dimethylphenyl)methyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-46-4
CMF C17 H21 N3 O3



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 303020-49-7 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-(trifluoromethyl)-, phenylmethyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-48-6
CMF C15 H14 F3 N3 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 303020-51-1 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-, 2-cyclohexylethyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-50-0
CMF C15 H23 N3 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 303020-53-3 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-, cyclohexylmethyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-52-2
CMF C14 H21 N3 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 303020-55-5 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-, (2-chlorophenyl)methyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-54-4
CMF C14 H14 Cl N3 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 303020-57-7 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-, [2-(trifluoromethyl)phenyl]methyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-56-6
CMF C15 H14 F3 N3 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 303020-59-9 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-, 1-phenylethyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-58-8
CMF C15 H17 N3 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 303020-61-3 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine, 4,5,6,7-tetrahydro-5-[[4-(phenylmethyl)-1-piperidinyl]carbonyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-60-2
CMF C19 H24 N4 O



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 303020-63-5 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxamide, 1,4,6,7-tetrahydro-N-methyl-N-(phenylmethyl)-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-62-4
CMF C15 H18 N4 O



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 303020-64-6 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-2-[(1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)carbonyl]- (9CI) (CA INDEX NAME)



RN 303020-65-7 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine, 5-(3,3-dimethyl-1-oxobutyl)-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 303020-66-8 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine, 4,5,6,7-tetrahydro-5-(1-oxo-3-phenyl-2-propynyl)- (9CI) (CA INDEX NAME)



RN 303020-67-9 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine, 4,5,6,7-tetrahydro-5-(1-oxo-3-phenyl-2-propynyl)-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-66-8
CMF C15 H13 N3 O



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 303020-68-0 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine, 5-[(2E)-3-[4-(1,1-dimethylethyl)phenyl]-1-oxo-2-propenyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 303020-69-1 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine, 5-[(2E)-3-[4-(1,1-dimethylethyl)phenyl]-1-oxo-2-propenyl]-4,5,6,7-tetrahydro-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-68-0
CMF C19 H23 N3 O

Double bond geometry as shown.



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 303020-70-4 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine, 5-(bicyclo[2.2.1]hept-2-ylacetyl)-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 303020-71-5 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine, 5-(bicyclo[2.2.1]hept-2-ylacetyl)-4,5,6,7-tetrahydro-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-70-4
CMF C15 H21 N3 O



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 303020-72-6 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine, 4,5,6,7-tetrahydro-5-(4-pentylbenzoyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 303020-74-8 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine, 4,5,6,7-tetrahydro-5-(4-pentylbenzoyl)-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-73-7
CMF C18 H23 N3 O



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 303020-75-9 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine, 4,5,6,7-tetrahydro-5-[4-(trifluoromethoxy)benzoyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 303020-77-1 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine, 4,5,6,7-tetrahydro-5-[4-(trifluoromethyl)benzoyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-76-0
CMF C14 H12 F3 N3 O



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 303020-79-3 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine, 4,5,6,7-tetrahydro-5-[4-(2-methylpropyl)benzoyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-78-2
CMF C17 H21 N3 O



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 303020-81-7 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine, 5-(4-chlorobenzoyl)-4,5,6,7-tetrahydro-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-80-6
CMF C13 H12 Cl N3 O



CM 2

CRN 144-62-7
CMF C2 H2 O4



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 6 OF 25 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:654406 CAPLUS
DOCUMENT NUMBER: 133:222577
TITLE: Preparation of aminoalkoxyacetophenone, 1-alkenoyl-2-aminoalkoxybenzene derivatives and analogs for the treatment of inflammation and osteoporosis
INVENTOR(S): Ohara, Takashi; Shimano, Masanao; Nagahara, Michiko; Ichikawa, Kiyonoshin; Awa, Takao; Nogimori, Katsumi
PATENT ASSIGNEE(S): Kaken Pharmaceutical Co., Ltd., Japan

Searched by Barb O'Bryen, STIC 308-4291

SOURCE: Jpn. Kokai Tokkyo Koho, 24 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2000256286	A2	20000919	JP 1999-65636	19990311

PRIORITY APPLN. INFO.: JP 1999-65636 19990311
OTHER SOURCE(S): MARPAT 133:222577
GI



I



II

AB The title compds. I [ring A = arom. ring, etc.; R1 = H, alkyl, etc.; R2 = H, halo, etc.; B = (un)substituted alkylene, etc.; R3, R4 = H, (un)substituted alkyl, etc.; X = carbonyl, etc.; Y = O, etc.] are prepd. An in vitro assay using macrophages treated with LPS was performed: in the presence of the title compd. II at 10-6 M, the amt. of interleukin 6 secreted was 15415.+-.1360 pg, vs. 23474.+-.2404 pg in controls. Formulations are given.

IT **292154-83-7P 292154-84-8P 292154-85-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of aminoalkoxyacetophenone and 1-alkenoyl-2-aminoalkoxybenzene derivs. for treatment of inflammation and osteoporosis)

RN 292154-83-7 CAPLUS
CN 2-Propen-1-one, 3-(2-furanyl)-1-[2-[3-(3,4,6,7-tetrahydro-3-methyl-5H-imidazo[4,5-c]pyridin-5-yl)propoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 292154-84-8 CAPLUS
CN 2-Propen-1-one, 3-(2-furanyl)-1-[2-[3-[3,4,6,7-tetrahydro-3-(phenylmethyl)-5H-imidazo[4,5-c]pyridin-5-yl]propoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 292154-85-9 CAPLUS
CN 2-Propen-1-one, 3-(2-furanyl)-1-[2-[3-(1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propoxy]phenyl]- (9CI) (CA INDEX NAME)



L14 ANSWER 7 OF 25 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1999:460401 CAPLUS
DOCUMENT NUMBER: 131:87906
TITLE: Preparation of tetrahydrobenzindole derivatives for treatment and prevention of diseases caused by abnormality in serotonin regulatory system
INVENTOR(S): Kikuchi, Chika; Ando, Takashi; Fuji, Kazuyuki; Okuno, Masayo; Satoh, Eriko; Shiiyama, Masako; Ushiroda, Osamu; Koyama, Masao; Hiranuma, Toyokazu
PATENT ASSIGNEE(S): Meiji Seika Kaisha, Ltd., Japan
SOURCE: PCT Int. Appl., 139 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9933804	A1	19990708	WO 1998-JP5827	19981222
W: CA, CN, JP, KR, NO, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
JP 11189585	A2	19990713	JP 1997-358381	19971225
CA 2316388	AA	19990708	CA 1998-2316388	19981222
EP 1057814	A1	20001206	EP 1998-961493	19981222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
NO 2000003285	A	20000823	NO 2000-3285	20000622
US 6498251	B1	20021224	US 2001-582416	20010308

PRIORITY APPLN. INFO.:
JP 1997-358380 A 19971225
JP 1997-358381 A 19971225
JP 1998-85913 A 19980331
JP 1998-136872 A 19980519
JP 1998-229709 A 19980814

JP 1998-319336 A 19981110
WO 1998-JP5827 W 19981222
OTHER SOURCE(S): MARPAT 131:87906

GI



I

AB Compds. I [.alpha. = Q1, etc.; R1 = H, alkyl, etc.; R2 = H, halo, etc.; X = NR10, etc. (R10 = H, etc.); n = 2 to 6; R3 = H, etc.] are prepd. Thus, 2a-(4-bromobutyl)-2a,3,4,5-tetrahydro-1H-benz[cd]indol-2-one 150 mg was reacted with 2,3,4,9-tetrahydro-1H-pyrido[2,4-b]indole 168 mg to give 2a-[4-(2,3,4,9-tetrahydro-1H-pyrido[2,4-b]indole)butyl]-2a,3,4,5-tetrahydro-1H-benz[cd]indol-2-one 73 mg, showing Ki values 227 nM in affinity test to 5-HT7 receptor, and 7 nM in affinity test to 5-HT2 receptor.

IT **230301-50-5P 230301-52-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(tetrahydrobenzindole derivs. for treatment and prevention of diseases caused by abnormality in serotonin regulatory system)

RN 230301-50-5 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-(1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)butyl]- (9CI) (CA INDEX NAME)



RN 230301-52-7 CAPLUS
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-(1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)butyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 8 OF 25 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1998:612094 CAPLUS
DOCUMENT NUMBER: 129:245172
TITLE: Preparation of 4,4-difluoro-2,3,4,5-tetrahydro-1H-1-benzazepine derivatives as oxytocin antagonists
INVENTOR(S): Matsuhisa, Akira; Murakami, Takeshi; Sakuda, Shuichi; Kawano, Noriyuki; Shibasaki, Kumiko; Tanaka, Akihiro
PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9839325	A1	19980911	WO 1998-JP916	19980305
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, GW, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9861204	A1	19980922	AU 1998-61204	19980305
EP 987264	A1	20000322	EP 1998-905779	19980305
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
US 6340678	B1	20020122	US 1999-380683	19990902

PRIORITY APPLN. INFO.: JP 1997-52163 A 19970306
WO 1998-JP916 W 19980305

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title 4,4-Difluoro-2,3,4,5-tetrahydro-1H-1-benzazepine derivs. represented by formula (I) or salts thereof (wherein A is 5-membered heteroarylene; B is optionally substituted aryl or 5- or 6-membered heteroaryl; D is carbonyl or lower alkylene; R1 is -NR3R4, -O-(lower alkyl) or OH; R2 is optionally halogenated lower alkyl, -O-(lower alkyl), -S-(lower alkyl) or -CO-(lower alkyl); R3 and R4 are each independently hydrogen, lower alkyl or the like; and n is 0, 1 or 2). The above compds.

exhibit the oxytocin antagonism and are effective in inhibiting threatened premature birth or abortion, or precesarean birth and useful as remedies for dysmenorrhea and so on (no data). Thus, 1H-benzoazepin-5-ylideneacetic acid deriv. (II; R = OH) was condensed with 2-(piperazin-1-yl)ethanol using DCC at room temp. for 18 h to give II (R = Q).

IT **213021-71-7P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of difluorotetrahydrobenzazepine derivs. as oxytocin antagonists)

RN 213021-71-7 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5-[2-oxo-2-(1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethylidene]-, monohydrochloride, (5Z)- (9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.



● HCl

REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 9 OF 25 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1998:484944 CAPLUS
DOCUMENT NUMBER: 129:109089
TITLE: Preparation of oxopyridinylmethylimidazolylmethylbenzonitriles and related compounds as inhibitors of farnesyl-protein transferase.
INVENTOR(S): Young, Steven D.; Anthony, Neville J.; Graham, Samuel L.; Tran, Lekhanh O.; Bell, Ian M.; Desolms, S. Jane; Gomez, Robert P.; Kuo, Michelle Sparks; Lumma, William C., Jr.; Perlow, Debra S.; Shaw, Anthony W.; Wai, John S.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA; et al.
SOURCE: PCT Int. Appl., 220 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9829119	A1	19980709	WO 1997-US23893	19971222
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9857195	A1	19980731	AU 1998-57195	19971222
US 5939439	A	19990817	US 1997-995744	19971222
EP 951285	A1	19991027	EP 1997-953451	19971222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2001507699	T2	20010612	JP 1998-530217	19971222
US 6077853	A	20000620	US 1999-300910	19990428

PRIORITY APPLN. INFO.:

US 1996-33990P	P	19961230
GB 1997-2211	A	19970204
US 1997-995744	A3	19971222
WO 1997-US23893	W	19971222

OTHER SOURCE(S): MARPAT 129:109089

AB (R8)rVA1[C(R1)2]nA2[C(R1)2]n[W(R9)q]t[C(R2)2]pX[C(R2)2]pYR3R4R5QR6aR6bR6cR6dR6e [Q = 4-7 membered N-heterocyclylacyl; Y = 5-7 membered (hetero)cyclyl; R1, R2 = H, aryl, heterocyclyl, cycloalkyl, alkenyl, alkynyl, (substituted) alkyl, etc.; R3-R5, R6a-R6e = H, (substituted) aryl, heterocyclyl, alkyl, cycloalkyl, alkenyl, alkynyl, halo, perfluoroalkyl, etc.; adjacent R6a-R6e = CH:CHCH:CH, (CH2)3-4, CH:CHCH2, etc.; R8 = H, (substituted) alkyl, aryl, heterocyclyl, cycloalkyl, alkenyl, alkynyl, perfluoroalkyl, F, Cl, Br, etc.; R9 = H, (substituted) alkyl, alkenyl, alkynyl, perfluoroalkyl, F, Cl, Br, etc.; A1, A2 = bond, CH:CHV = H, heterocyclyl, aryl, alkyl, etc. W = heterocyclyl; X = bond, CH:CH, O, CO, S, SO, SO2, CO2, imino, etc.; n, p = 0-4; q = 0-3; r = 0-5; t = 0, 1], were prepd. Thus, 4-(2-oxo-2H-pyridin-1-yl)benzyl bromide (prepn. given) and 4-(1-trityl-1H-imidazol-4-ylmethyl)benzonitrile were refluxed in MeCN to give a residue which was refluxed 2 h in MeOH to give 4-[3-[4-(2-oxo-2H-pyridin-1-yl)benzyl]-3H-imidazol-4-ylmethyl]benzonitrile. Title compds. inhibited ras farnesyl transferase with IC50<50 .mu.M.

IT **210037-52-8P 210037-53-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of oxopyridinylmethylimidazolylmethylbenzonitriles and related compds. as inhibitors of farnesyl-protein transferase)

RN 210037-52-8 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 4-(4-cyanophenyl)-1,4,6,7-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 210037-53-9 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 3-[(5-chloro-2-oxo[1(2H),2'-bipyridin]-5'-yl)methyl]-4-(4-cyanophenyl)-3,4,6,7-tetrahydro-,

1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 10 OF 25 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1997:85131 CAPLUS
DOCUMENT NUMBER: 126:104085
TITLE: Preparation of benzoic acid derivatives as 5-HT4 receptor agonists
INVENTOR(S): Suzuki, Takeshi; Iwaoka, Kyoshi; Naito, Makoto; Myata, Keiji; Kamato, Takeshi; Oota, Mitsuaki
PATENT ASSIGNEE(S): Yamanouchi Pharma Co Ltd, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 25 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08325234	A2	19961210	JP 1995-131264	19950530

PRIORITY APPLN. INFO.: JP 1995-131264 19950530
OTHER SOURCE(S): MARPAT 126:104085
GI For diagram(s), see printed CA Issue.
AB The title compds. (Ia and Ib; Im = imidazolyl ring; A ring = 4-8 numbered cycloalkyl; n = 0-2; R2, R5, R6 = H, alkyl; B ring = 4-8 numbered N-contg. heterocyclyl; R3 = halo; R4 = lower alkoxy) are prepd. I, possessing 5-HT4 receptor antagonism, are useful for prevention and treatment of central and peripheral nervous system, digestive system, cardiovascular system, and urinary system diseases. Thus, 6-(tert-butoxycarbonylamino)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine was treated with aq. HCl to give the title compd. 6-amino-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine. I showed 5-HT4 receptor antagonism.
IT **185796-85-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of benzoic acid derivs. as 5-HT4 receptor agonists)
RN 185796-85-4 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine, 5-(4-amino-5-chloro-2-methoxybenzoyl)-4,5,6,7-tetrahydro-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 185796-84-3
CMF C14 H15 Cl N4 O2



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



L14 ANSWER 11 OF 25 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1996:436546 CAPLUS
DOCUMENT NUMBER: 125:221700
TITLE: Solid phase synthesis of tetrahydroisoquinolines and tetrahydroimidazopyridines
AUTHOR(S): Hutchins, Steven M.; Chapman, Kevin T.
CORPORATE SOURCE: Dep. Mol. Design Diversity, Merck Res. Lab., Rahway, NJ, 07065, USA
SOURCE: Tetrahedron Letters (1996), 37(28), 4865-4868
CODEN: TELEAY; ISSN: 0040-4039
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 125:221700
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The prepn. of 1,2,3,4-tetrahydroisoquinolines I (R1 = Me, Et, CO2Me, R2 = H, Me, OH)and II (R3 = Ph, 2-MeC6H4, 4-O2NC6H4, 2-furyl, etc.) and 4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridines III (R1 = H, CO2Me) on a solid support has been developed. The route utilizes substituted m-tyramines, histamines and various arom., aliph. and heterocyclic aldehydes.

IT **181184-56-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(solid phase synthesis of tetrahydroisoquinolines and -imidazopyridines)

RN 181184-56-5 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-acetamide, N-(2-amino-2-oxoethyl)-1,4,6,7-tetrahydro-4-(2-methylphenyl)-N-propyl- (9CI) (CA INDEX NAME)



L14 ANSWER 12 OF 25 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1995:721205 CAPLUS
DOCUMENT NUMBER: 123:111747
TITLE: Preparation of antibacterial 1-methylcarbapenem derivatives
INVENTOR(S): Oida, Sadao; Tanaka, Teruo; Konosu, Toshuki; Mori, Makoto; Myaoka, Takeo; Tajima, Kazu
PATENT ASSIGNEE(S): Sankyo Co, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 55 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07101959	A2	19950418	JP 1993-244299	19930930

PRIORITY APPLN. INFO.: JP 1993-244299 19930930
OTHER SOURCE(S): MARPAT 123:111747
GI



I

AB Title compds. I [R1 = H, protecting group; R2 = H, protecting group, alkyl, alkenyl, C(:NR3); R3 = H, protecting group; R4 = H, alkyl, amino; A = cyclic substituent], useful as antibacterials (no data), are prepd. Thus, (2S,4S)-4-acetylthio-1-(4-nitrobenzyloxycarbonyl)-2-[(1S,4S)-5-(4-nitrobenzyloxycarbonyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl]carbonylpyrrolidine (prepn. given) was treated with NaOMe in MeOH-THF and the product was reacted with (1R,5R,6S)-6-[(R)-1-hydroxyethyl]-1-methyl-2-(diphenylphosphoryloxy)carbapenem-3-carboxylic acid 4-nitrobenzyl ester in MeCN contg. diisopropylethylamine to give (1R,5S,6S)-6-(R)-1-hydroxyethyl-1-methyl-2-[[(2S,4S)-1-(4-nitrobenzyloxycarbonyl)-2-[[(2S,4S)-5-(4-nitrobenzyloxycarbonyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl]carbonyl]pyrrolidin-4-yl]thio]carbapenem-3-carboxylic acid 4-nitrobenzyl ester. Pharmaceutical compns. contg. I are described.

IT **165893-60-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of antibacterial 1-methylcarbapenem derivs.)

RN 165893-60-7 CAPLUS

CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-(1-hydroxyethyl)-4-methyl-3-[[1-[[(4-nitrophenyl)methoxy]carbonyl]-5-[(1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)carbonyl]-3-pyrrolidinyl]thio]-7-oxo-, (4-nitrophenyl)methyl ester, [4R-[3(3S*,5S*),4.alpha.,5.beta.,6.beta.(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **165893-88-9P**

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of antibacterial 1-methylcarbapenem derivs.)

RN 165893-88-9 CAPLUS

CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-(1-hydroxyethyl)-4-methyl-7-oxo-3-[[5-[(1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)carbonyl]-3-pyrrolidinyl]thio]-, monohydrochloride, [4R-[3(3S*,5S*),4.alpha.,5.beta.,6.beta.(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



HCl

L14 ANSWER 13 OF 25 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1990:216653 CAPLUS
DOCUMENT NUMBER: 112:216653
TITLE: Synthesis of 6-aryl-4,5-dibenzamido-1,2,3,6-tetrahydropyridines
AUTHOR(S): Stocker, Fred B.; Evans, April J.
CORPORATE SOURCE: Dep. Chem., Macalester Coll., St. Paul, MN, 55105, USA
SOURCE: Journal of Organic Chemistry (1990), 55(10), 3370-3
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 112:216653
GI



I



II

AB Bamberger reaction of 4-aryltetrahydroimidazo[4,5-c]pyridines I (R = Me, OMe, Cl; R1 = H) gave predominately I (R1 = CH2Ph) with only small amts. of title compds. II (R1 = CH2Ph). Reaction of I (R1 = Me), however, gave II (R1 = Me) in 65-68% yield.
IT **126036-49-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 126036-49-5 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine, 5-benzoyl-4,5,6,7-tetrahydro-4-(4-methylphenyl)- (9CI) (CA INDEX NAME)



L14 ANSWER 14 OF 25 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1985:105733 CAPLUS
DOCUMENT NUMBER: 102:105733
TITLE: Anti-ulcer and antisecretory activity of selected imidazopiperidines
AUTHOR(S): Arcari, G.; Bernardi, L.; Cimaschi, R.; Falconi, G.; Luini, F.; Scarponi, U.
CORPORATE SOURCE: Farmitalia Carlo Erba S.p.A., Milan, I-20146, Italy
SOURCE: Arzneimittel-Forschung (1984), 34(11), 1467-71
CODEN: ARZNAD; ISSN: 0004-4172
DOCUMENT TYPE: Journal
LANGUAGE: English
GI

Searched by Barb O'Bryen, STIC 308-4291



I II

AB New thioureas and ureas, 4,5,6,7-tetrahydroimidazo[4,5-c]pyridine derivs. I and II (X = S, O) with antiulcer and antisecretory activities, were synthesized, and their structure-activity relations examd. For I and II (R1 = R2 = H and X = S), a low level of antiulcer activity was obsd. when R3 is a cyclohexyl, Ph, or alkyl. Reducing the ring size (R3 = cyclopentyl, cyclopropyl) or shortening the chain (R3 = Me) improved the activity. The highest antiulcer activity combined with the highest antisecretory activity was obsd. when R3 = CHMe2. When X = S, R1 = H, and R3 = CHMe2, the introduction of a substituent in position 4 was detrimental for the potency, notably when R2 was a Ph, a heterocyclic, or branched alkyl. A still good level of antiulcer activity was obsd. only when R2 was Et. The Me and Pr derivs. showed good antiulcer activity, with the 1-substituted derivs. showing the higher potency. When X = O, a good antiulcer activity and reasonable level of antisecretory activity were obsd.

IT **70651-72-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and alkylation of)

RN 70651-72-8 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 4-ethyl-1,4,6,7-tetrahydro-, phenylmethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT **70651-74-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and amidation and deprotection of)

RN 70651-74-0 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 3,4-diethyl-3,4,6,7-tetrahydro-, phenylmethyl ester (9CI) (CA INDEX NAME)



L14 ANSWER 15 OF 25 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1983:470725 CAPLUS
DOCUMENT NUMBER: 99:70725
TITLE: 1- or 1,3-Substituted 4,5,6,7-tetrahydroimidazo[4,5-c]pyridines
INVENTOR(S): Yutilov, Yu. M.; Eilazyan, O. G.
PATENT ASSIGNEE(S): Institute of Physical-Organic Chemistry and Coal Chemistry, Academy of Sciences, Ukrainian S.S.R., USSR
SOURCE: U.S.S.R. From: Otkrytiya, Izobret., Prom. Obraztsy, Tovarnye Znaki 1983, (10), 106.
CODEN: URXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Russian
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
SU 1004385	A1	19830315	SU 1981-3258836	19810309

PRIORITY APPLN. INFO.: SU 1981-3258836 19810309
OTHER SOURCE(S): CASREACT 99:70725
GI



I II

AB Title compds. I (R = Me, Et; R1 = H, Me) are prepd. by a simplified procedure with increased yield and expanded scope by treating methoxy-substituted 5-(.beta.-phenyl-.beta.-hydroxyethyl)-4,5,6,7-tetrahydroimidazo[4,5-c]pyridines II (same R, R1; R2 = H, OMe) with HCl in refluxing aq. alc.

IT **86674-44-4D**, derivs.
RL: RCT (Reactant); RACT (Reactant or reagent)
(hydrolysis of)

RN 86674-44-4 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-ethanol, 1,4,6,7-tetrahydro-.alpha.-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



L14 ANSWER 16 OF 25 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1981:569075 CAPLUS
DOCUMENT NUMBER: 95:169075
TITLE: New synthesis of spinaceamine derivatives
AUTHOR(S): Yutilov, Yu. M.; Eilazyan, O. G.
CORPORATE SOURCE: Inst. Fiz.-Org. Khim. Uglekhim., Donetsk, 340048, USSR
SOURCE: Khimiya Geterotsiklicheskikh Soedinenii (1981), (7), 992
CODEN: KGSSAQ; ISSN: 0453-8234
DOCUMENT TYPE: Journal
LANGUAGE: Russian
GI





AB Spinaceamine derivs. I (R = Et, CH2CH2OH), II (R = Me, benzyl, CH2CH2OH) and III were prepd. in 69-98% yield by redn. of quaternary salts of 1- and 3-substituted imidazo[4,5-c]pyridine with NaBH4 or KBH4 in aq. or alc. soln. at room temp.

IT **79457-28-6P 79457-30-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 79457-28-6 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-ethanol, 3,4,6,7-tetrahydro-3-methyl-, compd. with 2,4,6-trinitrophenol (9CI) (CA INDEX NAME)

CM 1

CRN 79457-27-5
CMF C9 H15 N3 O



CM 2

CRN 88-89-1
CMF C6 H3 N3 O7



RN 79457-30-0 CAPLUS
CN 3H-Imidazo[4,5-c]pyridine, 4,5,6,7-tetrahydro-3-methyl-5-(phenylmethyl)-, compd. with 2,4,6-trinitrophenol (9CI) (CA INDEX NAME)

CM 1

CRN 79457-29-7
CMF C14 H17 N3



CM 2

CRN 88-89-1
CMF C6 H3 N3 O7



L14 ANSWER 17 OF 25 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1979:439486 CAPLUS
DOCUMENT NUMBER: 91:39486
TITLE: 4,5,6,7-Tetrahydroimidazo[4,5-c]pyridine derivatives
INVENTOR(S): Arcari, Guiliana; Bernardi, Luigi; Falconi, Giovanni; Scarponi, Ugo
PATENT ASSIGNEE(S): Societa Farmaceutici Italia S.p.A., Italy
SOURCE: Belg., 18 pp.
CODEN: BEXXAL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
BE 871985	A1	19790301	BE 1978-191705	19781114
NL 7811125	A	19800211	NL 1978-11125	19781109
NL 181657	B	19870504		
NL 181657	C	19871001		
AU 7841490	A1	19800214	AU 1978-41490	19781110

AU 520102	B2	19820114			
CA 1113468	A1	19811201	CA 1978-316132	19781110	
CH 636875	A	19830630	CH 1978-11596	19781110	
AT 7808117	A	19791215	AT 1978-8117	19781113	
AT 357533	B	19800710			
DK 7805026	A	19800208	DK 1978-5026	19781113	
DK 146159	B	19830711			
DK 146159	C	19831205			
FR 2433022	A1	19800307	FR 1978-31960	19781113	
FR 2433022	B1	19810612			
GB 2028798	A	19800312	GB 1978-44281	19781113	
GB 2028798	B2	19820811			
US 4223146	A	19800916	US 1978-959506	19781113	
ZA 7806388	A	19791031	ZA 1978-6388	19781114	
SE 7811761	A	19800208	SE 1978-11761	19781114	
SE 438150	B	19850401			
SE 438150	C	19850711			
JP 55024158	A2	19800221	JP 1978-139477	19781114	
JP 58010387	B4	19830225			
DE 2849572	A1	19800221	DE 1978-2849572	19781115	
DE 2849572	C2	19860626			
SU 791241	D	19801223	SU 1978-2685600	19781115	

PRIORITY APPLN. INFO.: IT 1978-26562 19780807

GI



I



II

AB Thiocarbamoylimidazopyridines I (R = C1-4 alkyl; R1 = H, C1-4 alkyl; R2 = C1-4 aliph.) were prepd. Thus, II (R = R3 = H) was treated with ClCO2CH2Ph and EtBr to give II (R = Et, R3 = CO2CH2Ph), which was treated with HBr to give II (R = Et, R3 = H). Treatment of the latter compd. with Me2CHNCO gave I (R = R1 = Et, R2 = CHMe2), which had an antiulcer ED50 of 3.5 mg/kg orally in rats with little anticholinergic activity.

IT **70651-72-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and alkylation of)

RN 70651-72-8 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 4-ethyl-1,4,6,7-tetrahydro-, phenylmethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



Same as previous

● HCl

IT **70651-74-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 70651-74-0 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 3,4-diethyl-3,4,6,7-tetrahydro-, phenylmethyl ester (9CI) (CA INDEX NAME)



L14 ANSWER 18 OF 25 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1968:87234 CAPLUS
DOCUMENT NUMBER: 68:87234
TITLE: Synthetic spinaceamines
AUTHOR(S): Vitali, Tullo; Mossini, Ferdinando; Bertaccini, Giulio
CORPORATE SOURCE: Univ. Parma, Parma, Italy
SOURCE: Farmaco, Edizione Scientifica (1967), 22(10), 821-45
CODEN: FRPSAX; ISSN: 0430-0920
DOCUMENT TYPE: Journal
LANGUAGE: Italian
GI For diagram(s), see printed CA Issue.
AB Histamine is treated with aldehydes and ketones to give I and II. Thus, a soln. of 0.01 mole histamine in 10 ml. MeOH is treated with 1.6 g. NaOH in 3 ml. water and 0.04 mole Me2CO in 27 ml. MeOH; the mixt. is heated 10-24 hrs. to give 80% 5,5-dimethylspinaceamine (III), m. 188-9.degree. (EtOH), dihydrochloride hydrate m. 253-4.degree. (EtOH-C6H6), dipicrate dihydrate m. 236-7.degree. (water). Similarly prepd. are the following I (X = Y = H) (R, R1, m.p., m.p. dipicrate, % yield, and salt m.p. given): Me, Et, -, -, -, HCl 244-6.degree. (decompn.) (EtOH); Me, Ph, -, -, -, 2HCl 240-2.degree. (EtOH), dipicrate dihydrate 212-13.degree. (aq. EtOH); Et, Ph, -, 197-8.degree. (aq. EtOH), -, 2HCl 228-30.degree. (EtOH); Me, 2-furyl, -, 168-9.degree. (EtOH), -, H2O 115-16.degree. (water); Me, 2-thienyl, -, -, -, H2O 116-18.degree. (water); H, tert-Bu, 166-7.degree. (water), -, 85, dipicrate hydrate 206-7.degree. (water); H, Ph, 201-2.degree. (water), -, 95, 2HCl.1/2H2O 252-4.degree. (EtOH), 2HNO3 207-9.degree. (EtOH), dipicrate hydrate 221-2.degree. (aq. EtOH); H, PhCH2, -, -, -, 2HCl.H2O 149-50.degree. (decompn.) (EtOH), dipicrate hydrate 148-50.degree. (aq. EtOH); H, o-ClC6H4, 204-5.degree., -, 95, dipicrate hydrate 256.degree. (decompn.) (EtOH); H, m-ClC6H4, 178-9.degree. (water), -, 95, dipicrate hydrate 203-4.degree. (EtOH); H, p-ClC6H4, 179-80.degree., -, 95, dipicrate hydrate 222-3.degree. (EtOH); H, m-tolyl, -, 279-80.degree. (EtOH), -, 1/2H2O 169-70.degree. (water); H,

p-tolyl, 177-8.degree. (water), 228.degree. (EtOH), 95, -; H, o-O2NC6H4, 216-17.degree. (decompn.) (water), 220-1.degree. (EtOH), 80, -; H, m-O2NC6H4, -, 281-2.degree. (EtOH), -, 1/2H2O 177-8.degree. (water); H, p-O2NC6H4, 235-6.degree. (decompn.) (water), 178-80.degree. (water), 80, -; H, p-Me2NC6H4, -, -, -, H2O 186-7.degree. (water); H, o-MeOC6H4, -, 243-4.degree. (EtOH), -, H2O 129-30.degree. (water,) 2HCl.H2O 257-8.degree. (EtOH); H, m-MeOC6H4, 158-9.degree. (water), -, 75, dipicrate hydrate 228-9.degree. (EtOH); H, p-MeOC6H4, 186-7.degree. (water), -, 80, dipicrate hydrate 221-2.degree. (aq. EtOH); H, 3,4-(MeO)2C6H3, -, 233.degree. (aq. EtOH), -, 2HCl.1/2H2O 140-1.degree. (decompn.) (EtOH); H, 3,4,5-(MeO)3C6H2, 155-6.degree. (water), -, 80, picrate hydrate 165-6.degree. (aq. EtOH); H, 3,4-(CH2O2)C6H3, 187-8.degree. (water), 217-18.degree. (EtOH), 85, -; H, 2-methyl-3-hydroxy-5-hydroxy-methyl-4-pyridyl, 252.degree. (decompn.) (water), 234.degree. (decompn.) (EtOH), 90, -; RR1 = (CH2)5, -, -, -, -, 1/4H2O 210-11.degree. (water); RR1 = (CH2)4, -, -, -, -, 1/2H2O 161-2.degree. (water). N.M.R. data for III and I (X = Y = R = H, R1 = Ph) are given; uv and chromatographic data for the prepd. compds. are also given. Histamine is treated with an equimolar amt. of p-MeOC6H4CHO at a low temp. to give 80% N',N'-(p-methoxybenzylidene)histamine, m. 111-13.degree. (C6H6). Similarly prepd. are the following II (R = H) (R1, m.p., and % yield given): p-ClC6H4, 125-7.degree. (C6H6), 98; p-HOC6H4, 162-4.degree. (EtOH-ether), 78; uv data for the prepd. II are given. A soln. of 2.5 g. III-2HCl in water is treated with 4.2 g. BzCl in the presence of 2.5 g. NaOH (10% soln.) to give .apprx.1.2 g. I (X = Y = Bz, R = R1 = Me), m. 223-4.degree. (aq. EtOH). Similarly prepd. is I (X = R = H, R1 = Ph, Y = Ac), m. 194-5.degree. (water). A mixt. of 2.0 g. III, 2.5 g. H2CO (35%), and 5.0 g. HCO2H (85%) is refluxed 5 hrs. to give I (X = H, R = R1 = Y = Me), m. 143-3.5.degree. (Me2CO), 2HCl salt m. 242-6.degree. (alc.-Me2CO), dipicrate m. 229.5-30.5.degree. (decompn.) (water). A soln. of 3 g. I (R = X = Y = H, R1 = Ph) in 12 ml. concd. H2SO4 is treated at 5-10.degree. with 1.0 ml. fuming HNO3 to give 2.5 g. I (R = X = Y = H, R1 = m-O2NC6H4) (IV), m. 175-6.degree. (aq. alc.). IV (0.5 g.) in 16 ml. water contg. 0.5 g. KOH is treated with satd. KMnO4 to give m-O2NC6H4CO2H, m. 139-40.degree. (water). IV (4.0 g.) is treated with 7 g. Sn and 14 ml. HCl to give I (R = X = Y = H, R1 = m-H2NC6H4) (V), picrate m. 178-80.degree. (decompn.) (water). V is diazotized at 0.degree. with 1.2 g. NaNO2 and 6.5 ml. concd. HCl and the product is heated with 8.0 g. Cu2Cl2 in 23 ml. concd. HCl to give I (R = X = Y = H, R1 = m-ClC6H4), m. 177-8.degree. (water). A soln. prepd. from 1.0 g. I (X = R = H, R1 = Ph, Y = Ac), 2.0 g. concd. H2SO4, and 0.6 g. HOAc is treated at 5-10.degree. with 0.3 g. fuming HNO3 and 0.3 g. concd. H2SO4 to give I (X = R = H, R1 = m-O2NC6H4, Y = Ac), m. 218-19.degree. (water), which is treated with 20% HCl to give IV, m. 177-8.degree..

IT **18096-47-4P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 18096-47-4 CAPLUS

CN 3H-Imidazo[4,5-c]pyridine, 3,5-dibenzoyl-4,5,6,7-tetrahydro-4,4-dimethyl- (8CI) (CA INDEX NAME)



L14 ANSWER 19 OF 25 USPATFULL

ACCESSION NUMBER: 2002:344459 USPATFULL
TITLE: New use
INVENTOR(S): Besencon, Olivier, Allschwil, SWITZERLAND
Olsson, Rolf, Gnesta, SWEDEN
Ohman, Johan, Uppsala, SWEDEN
Caldirola, Patrizia, Uppsala, SWEDEN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002198189	A1	20021226
APPLICATION INFO.:	US 2001-45319	A1	20011109 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	SE 2000-4101	20001109
	US 2000-252156P	20001120 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: JEFFREY D. HSI, Fish & Richardson P.c., 225 Franklin Street, Boston, MA, 02110-2804
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
LINE COUNT: 1754
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of treatment or prophylaxis of SSAO-mediated complications in mammals including humans, comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of Formula (I): ##STR1##

in which R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as described in the specification.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **424837-38-7P**, Benzyl 4-ethyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate trifluoroacetate **424837-55-8P**, 4-Phenyl-5-(phenoxyacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine trifluoroacetate
(drug candidate; prepn. of tetrahydroimidazopyridine derivs. as SSAO inhibitors for treatment of diabetic complications)
RN 424837-38-7 USPATFULL
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 4-ethyl-1,4,6,7-tetrahydro-, phenylmethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 424837-37-6
CMF C16 H19 N3 O2

Same as 95 of 14



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 424837-55-8 USPATFULL
CN 1H-Imidazo[4,5-c]pyridine, 4,5,6,7-tetrahydro-5-(phenoxyacetyl)-4-phenyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 424837-54-7
CMF C20 H19 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT **424837-36-5P**, Methyl 4-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate **424837-40-1P**, Benzyl 4-phenyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate trifluoroacetate **424837-41-2P**, Benzyl 4-benzyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate **424837-43-4P**, Benzyl 4-propyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate trifluoroacetate **424837-45-6P**, Methyl 4-ethyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate trifluoroacetate **424837-47-8P**, Methyl 4-propyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate trifluoroacetate **424837-49-0P**, Methyl 4-phenyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate trifluoroacetate **424837-51-4P**, 4-Ethyl-5-(phenoxyacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine trifluoroacetate **424837-53-6P**, 4-Propyl-5-(phenoxyacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine trifluoroacetate **424837-57-0P**, Cyclopentyl 4-ethyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate trifluoroacetate **424837-59-2P**, Cyclopentyl 4-propyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate trifluoroacetate **424837-61-6P**, Cyclopentyl 4-phenyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate trifluoroacetate **424837-63-8P**, 4-Fluorophenyl 4-ethyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate trifluoroacetate

424837-65-0P, 4-Fluorophenyl 4-propyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate trifluoroacetate **424837-66-1P**, 2-Methoxyethyl 4-ethyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate **424837-67-2P**, 2-Methoxyethyl 4-propyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate **424837-68-3P**, 2-Methoxyethyl 4-phenyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate **424837-69-4P**, Benzyl 4-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate **424837-70-7P**, 4-Methyl-5-(phenoxyacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine **424837-71-8P**, Allyl 4-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate **424837-72-9P**, Allyl 4-ethyl-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate **424837-73-0P**, Allyl 4-propyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate **424837-74-1P**, 2,2,2-Trichloroethyl 4-ethyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate **424837-75-2P**, Allyl 4-benzyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate **424837-76-3P**, 2,2,2-Trichloroethyl 4-propyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate **424837-77-4P**, 2,2,2-Trichloroethyl 4-benzyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate **424837-78-5P**, 4-Nitrobenzyl 4-ethyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate **424837-79-6P**, 4-Nitrobenzyl 4-propyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate **424837-85-4P**, 4-Fluorophenyl 4-phenyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate trifluoroacetate
(drug candidate; prepn. of tetrahydroimidazopyridine derivs. as SSAO inhibitors for treatment of diabetic complications)

RN 424837-36-5 USPATFULL
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 424837-40-1 USPATFULL
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-phenyl-, phenylmethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 424837-39-8
CMF C20 H19 N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 424837-41-2 USPATFULL
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-(phenylmethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 424837-43-4 USPATFULL
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-propyl-, phenylmethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 424837-42-3
CMF C17 H21 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 424837-45-6 USPATFULL
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 4-ethyl-1,4,6,7-tetrahydro-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 424837-44-5
CMF C10 H15 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 424837-47-8 USPATFULL
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-propyl-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 424837-46-7
CMF C11 H17 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 424837-49-0 USPATFULL
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-phenyl-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 424837-48-9

CMF C14 H15 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 424837-51-4 USPATFULL
CN 1H-Imidazo[4,5-c]pyridine, 4-ethyl-4,5,6,7-tetrahydro-5-(phenoxyacetyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 424837-50-3
CMF C16 H19 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 424837-53-6 USPATFULL
CN 1H-Imidazo[4,5-c]pyridine, 4,5,6,7-tetrahydro-5-(phenoxyacetyl)-4-propyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 424837-52-5
CMF C17 H21 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 424837-57-0 USPATFULL
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 4-ethyl-1,4,6,7-tetrahydro-, cyclopentyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 424837-56-9
CMF C14 H21 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 424837-59-2 USPATFULL
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-propyl-, cyclopentyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 424837-58-1
CMF C15 H23 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 424837-61-6 USPATFULL
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-phenyl-, cyclopentyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 424837-60-5
CMF C18 H21 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 424837-63-8 USPATFULL
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 4-ethyl-1,4,6,7-tetrahydro-, 4-fluorophenyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 424837-62-7
CMF C15 H16 F N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 424837-65-0 USPATFULL
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-propyl-, 4-fluorophenyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 424837-64-9
CMF C16 H18 F N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 424837-66-1 USPATFULL
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 4-ethyl-1,4,6,7-tetrahydro-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)



RN 424837-67-2 USPATFULL
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-propyl-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)



RN 424837-68-3 USPATFULL
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-phenyl-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)



RN 424837-69-4 USPATFULL
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 424837-70-7 USPATFULL
CN 1H-Imidazo[4,5-c]pyridine, 4,5,6,7-tetrahydro-4-methyl-5-(phenoxyacetyl)- (9CI) (CA INDEX NAME)



RN 424837-71-8 USPATFULL

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-methyl-, 2-propenyl ester (9CI) (CA INDEX NAME)



RN 424837-72-9 USPATFULL
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 4-ethyl-1,4,6,7-tetrahydro-, 2-propenyl ester (9CI) (CA INDEX NAME)



RN 424837-73-0 USPATFULL
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-propyl-, 2-propenyl ester (9CI) (CA INDEX NAME)



RN 424837-74-1 USPATFULL
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 4-ethyl-1,4,6,7-tetrahydro-, 2,2,2-trichloroethyl ester (9CI) (CA INDEX NAME)



RN 424837-75-2 USPATFULL
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-(phenylmethyl)-, 2-propenyl ester (9CI) (CA INDEX NAME)



RN 424837-76-3 USPATFULL
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-propyl-, 2,2,2-trichloroethyl ester (9CI) (CA INDEX NAME)



RN 424837-77-4 USPATFULL
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-(phenylmethyl)-, 2,2,2-trichloroethyl ester (9CI) (CA INDEX NAME)



RN 424837-78-5 USPATFULL
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 4-ethyl-1,4,6,7-tetrahydro-, (4-nitrophenyl)methyl ester (9CI) (CA INDEX NAME)



RN 424837-79-6 USPATFULL
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-propyl-, (4-nitrophenyl)methyl ester (9CI) (CA INDEX NAME)



RN 424837-85-4 USPATFULL
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-phenyl-, 4-fluorophenyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 424837-84-3
CMF C19 H16 F N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



L14 ANSWER 20 OF 25 USPATFULL

ACCESSION NUMBER:	2002:340381 USPATFULL
TITLE:	Tetrahydrobenzindole derivatives
INVENTOR(S):	Kikuchi, Chika, Kanagawa, JAPAN Ando, Takashi, Kanagawa, JAPAN Fuji, Kazuyuki, Kanagawa, JAPAN Okuno, Masayo, Kanagawa, JAPAN Morita, Eriko, Kanagawa, JAPAN Imai, Masako, Kanagawa, JAPAN Ushiroda, Osamu, Kanagawa, JAPAN Koyama, Masao, Kanagawa, JAPAN Hiranuma, Toyokazu, Kanagawa, JAPAN
PATENT ASSIGNEE(S):	Meiji Seika Kaisha, Ltd., Tokyo, JAPAN (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6498251	B1	20021224	
	WO 9933804		19990807	
APPLICATION INFO.:	US 2001-582416		20010308	(9)
	WO 1998-JP5827		19981222	

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1997-358380	19971225
	JP 1997-358381	19971225
	JP 1998-85913	19980331
	JP 1998-136872	19980519
	JP 1998-229709	19980814
	JP 1998-319336	19981110

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Shah, Mukund J.
ASSISTANT EXAMINER:	Liu, Hong
LEGAL REPRESENTATIVE:	Sughrue Mion, PLLC
NUMBER OF CLAIMS:	12
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT:	4170

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds containing tetrahydrobenzindole which bind to serotonin receptor and are useful in treatment or prevention of disease induced by abnormality of central peripheral serotonin controlling functions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **230301-50-5P 230301-52-7P**
(tetrahydrobenzindole derivs. for treatment and prevention of diseases caused by abnormality in serotonin regulatory system)
RN 230301-50-5 USPATFULL
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-(1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)butyl]- (9CI) (CA INDEX NAME)



RN 230301-52-7 USPATFULL
CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-(1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)butyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L14 ANSWER 21 OF 25 USPATFULL

ACCESSION NUMBER:	2002:39930 USPATFULL
TITLE:	Inhibitors of prenyl-protein transferase
INVENTOR(S):	deSolms, S. Jane, Collegeville, PA, United States Shaw, Anthony W., Lansdale, PA, United States
PATENT ASSIGNEE(S):	Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6350755	B1	20020226	
APPLICATION INFO.:	US 2001-757218		20010109	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-175703P	20000112 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Kifle, Bruck
LEGAL REPRESENTATIVE:	Muthard, David A., Daniel, Mark R.
NUMBER OF CLAIMS:	18

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 3178
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to peptidomimetic macrocyclic compounds which inhibit prenyl-protein transferase and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting prenyl-protein transferase and the prenylation of the oncogene protein Ras.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **350687-92-2P 350687-93-3P**
(macrocyclic peptidomimetic inhibitors of prenyl-protein transferase for inhibiting prenylation of Ras oncoprotein)
RN 350687-92-2 USPATFULL
CN 3H-Imidazo[4,5-c]pyridine, 4-(4-cyano-3-fluorophenyl)-4,5,6,7-tetrahydro-5-[3-[[(3-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 350687-93-3 USPATFULL
CN 3H-Imidazo[4,5-c]pyridine, 4-(4-cyano-3-fluorophenyl)-4,5,6,7-tetrahydro-5-[3-[[(3-hydroxyphenyl)sulfonyl]amino]-1-oxopropyl]-3-methyl- (9CI) (CA INDEX NAME)



L14 ANSWER 22 OF 25 USPATFULL
ACCESSION NUMBER: 2002:13995 USPATFULL
TITLE: 4,4-difluoro-2,3,4,5-tetrahydro-1H-1-benzoazepine derivatives and drug compositions containing them
INVENTOR(S): Matsuhisa, Akira, Ushiku, JAPAN
Murakami, Takeshi, Tsukuba, JAPAN
Sakuda, Shuichi, Tokyo, JAPAN
Kawano, Noriyuki, Tsukuba, JAPAN
Shibasaki, Kumiko, Tsukuba, JAPAN
Tanaka, Akihiro, Tsuchiura, JAPAN
PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Tokyo, JAPAN

(non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6340678	B1	20020122	
	WO 9839325		19980911	
APPLICATION INFO.:	US 1999-380683		19990902	(9)
	WO 1998-JP916		19980305	
			19990902	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1997-52163	19970306

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Coleman, Brenda
LEGAL REPRESENTATIVE: Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 2188
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB 4,4-difluoro-2,3,4,5-tetrahydro-1H-1-benzoazepine compounds or salts thereof and pharmaceutical compositions containing 4,4-difluoro-2,3,4,5-tetrahydro-1H-1-benzoazepine compounds, or salts thereof, and a pharmaceutically acceptable carrier. The chemical structure of these compounds is characterized by a difluoro group on a ring carbon atom adjacent to an azepine ring carbon atom substituted with a methylidene group. Pharmaceutical compositions containing these compounds are particularly useful as oxytocin antagonists and are effective in inhibiting threatened premature birth or abortion and precesarean birth, and are effective as a remedy for dysmenorrhea and other such conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **213021-71-7P**
(prepn. of difluorotetrahydrobenzazepine derivs. as oxytocin antagonists)
RN 213021-71-7 USPATFULL
CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5-[2-oxo-2-(1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethylidene]-, monohydrochloride, (5Z)- (9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.



● HCl

L14 ANSWER 23 OF 25 USPATFULL

ACCESSION NUMBER:	2000:77368 USPATFULL
TITLE:	Inhibitors of farnesyl-protein transferase
INVENTOR(S):	Graham, Samuel L., Schwenksville, PA, United States Young, Steven D., Lansdale, PA, United States
PATENT ASSIGNEE(S):	Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6077853		20000620
APPLICATION INFO.:	US 1999-300910		19990428 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1997-995744, filed on 22 Dec 1997, now patented, Pat. No. US 5939439, issued on 17 Aug 1999

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Fan, Jane
LEGAL REPRESENTATIVE:	Muthard, David A., Daniel, Mark R.
NUMBER OF CLAIMS:	19
EXEMPLARY CLAIM:	1
LINE COUNT:	4987

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **210037-52-8P 210037-53-9P**
(prepn. of oxopyridinylmethylimidazolylmethylbenzonitriles and related compds. as inhibitors of farnesyl-protein transferase)

RN 210037-52-8 USPATFULL

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 4-(4-cyanophenyl)-1,4,6,7-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 210037-53-9 USPATFULL
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 3-[(5-chloro-2-oxo[1(2H),2'-bipyridin]-5'-yl)methyl]-4-(4-cyanophenyl)-3,4,6,7-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L14 ANSWER 24 OF 25 USPATFULL

ACCESSION NUMBER:	1999:96390 USPATFULL
TITLE:	Inhibitors of farnesyl-protein transferase
INVENTOR(S):	Anthony, Neville J., Hatfield, PA, United States Graham, Samuel L., Schwenksville, PA, United States Tran, Lekhanh O., Norristown, PA, United States Bell, Ian M., Harleysville, PA, United States deSolms, S. Jane, Norristown, PA, United States Gomez, Robert P., Perkasie, PA, United States Kuo, Michelle Sparks, Gwynedd Valley, PA, United States Lumma, Jr., William C., Pennsburg, PA, United States Perlow, Debra S., East Greenville, PA, United States Shaw, Anthony W., Lansdale, PA, United States Wai, John S., Harleysville, PA, United States Young, Steven D., Lansdale, PA, United States
PATENT ASSIGNEE(S):	Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5939439		19990817	
APPLICATION INFO.:	US 1997-995744		19971222	(8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-33990P	19961230 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Fan, Jane
LEGAL REPRESENTATIVE:	Muthard, David A., Daniel, Mark R.
NUMBER OF CLAIMS:	21

EXEMPLARY CLAIM: 1
LINE COUNT: 4949
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **210037-52-8P 210037-53-9P**
(prepn. of oxopyridinylmethylimidazolylmethylbenzonitriles and related compds. as inhibitors of farnesyl-protein transferase)
RN 210037-52-8 USPATFULL
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 4-(4-cyanophenyl)-1,4,6,7-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 210037-53-9 USPATFULL
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 3-[(5-chloro-2-oxo[1(2H),2'-bipyridin]-5'-yl)methyl]-4-(4-cyanophenyl)-3,4,6,7-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L14 ANSWER 25 OF 25 USPATFULL
ACCESSION NUMBER: 80:45756 USPATFULL
TITLE: 4,5,6,7-Tetrahydroimidazo-[4,5-c]-pyridine derivatives
INVENTOR(S): Arcari, Giuliana, Milan, Italy
Bernardi, Luigi, Milan, Italy
Falconi, Giovanni, Milan, Italy
Scarponi, Ugo, Milan, Italy
PATENT ASSIGNEE(S): Farmitalia Carlo Erba S.p.A., Milan, Italy (non-U.S. corporation)

NUMBER	KIND	DATE

Searched by Barb O'Bryen, STIC 308-4291

PATENT INFORMATION: US 4223146 19800916
APPLICATION INFO.: US 1978-959506 19781113 (5)

	NUMBER	DATE
PRIORITY INFORMATION:	IT 1978-26562	19780807

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Rotman, Alan L.
ASSISTANT EXAMINER: Harkaway, Natalia
LEGAL REPRESENTATIVE: Stevens, Davis, Miller & Mosher
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
LINE COUNT: 360
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds are disclosed of the general formula (I): ##STR1## wherein R.sub.1 is a lower alkyl having from 1 to 4 carbon atoms; R.sub.2 is hydrogen or a lower alkyl having from 1 to 4 carbon atoms; and R.sub.3 is a saturated or unsaturated straight or branched alkyl having from 1 to 4 carbon atoms. A process for making such compounds is also disclosed. These compounds are useful as antiulcer agents and as inhibitors of gastric secretion.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **70651-72-8P**
(prepn. and alkylation of)
RN 70651-72-8 USPATFULL
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 4-ethyl-1,4,6,7-tetrahydro-, phenylmethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT **70651-74-0P**
(prepn. of)
RN 70651-74-0 USPATFULL
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 3,4-diethyl-3,4,6,7-tetrahydro-, phenylmethyl ester (9CI) (CA INDEX NAME)



FILE 'CAOLD' ENTERED AT 10:46:40 ON 24 FEB 2003

Searched by Barb O'Bryen, STIC 308-4291

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

```
L1              STR
L3              STR
L4              STR
L6          585 SEA FILE=REGISTRY SSS FUL L1 NOT (L3 OR L4)
L8              STR
L10         165 SEA FILE=REGISTRY SUB=L6 SSS FUL L8
L13           0 SEA FILE=CAOLD ABB=ON  L10
```

FILE 'HOME' ENTERED AT 10:46:40 ON 24 FEB 2003